4DMedical (ASX:4DX) share price is lifting on its COVID-related technology

The healthcare company is moving to Phase 2 trials of its imaging technology that's helping COVID-19 patients.

| More on:
a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The  4DMedical Ltd (ASX: 4DX) share price is in the green this morning. That's after the healthcare company announced it will be conducting a clinical pilot with I-Med for its respiratory scanning technology.

At the time of writing, shares in the company are trading for $1.62 – up 1.57% after earlier hitting $1.65. The ASX All Ordinaries Index (ASX: XAO), meanwhile, is 0.75% lower.

Let's take a closer look at today's news.

4DMedical share price rises on latest announcement

In a statement to the ASX, 4DMedical announced an agreement to commence Phase Two of its clinical pilot program with I-MED Radiology Network (I-MED), after the successful completion of Phase One.

The company says its technology provided "valuable insights" into a plethora of respiratory diseases, including asthma, silicosis, and long-COVID. Long-COVID refers to the continuation of symptoms felt by some covid patients long after acquiring the infection.

Phase one trials were conducted in Victoria. 4DMedical says the next stage will be completed in a different state "over the remainder of the year". The company is still looking into a commercial partnership with I-MED going forward.

Investors clearly love today's announcement, judging by the rising 4DMedical share price.

Management commentary

4DMedical founder and CEO Andreas Fouras said:

We are very excited to be conducting a clinical pilot with I-MED – a leader of pioneering new medical imaging technologies – to provide doctors and patients with improved insight into their lung health. Phase One of the clinical pilot was an overwhelming success with radiologists and patients reporting strong positive feedback. Although the partnership is not generating revenue at this stage, we aim to secure a commercial XV LVAS contract with I-MED provided that Phase Two is successful.

I-MED General Manager of external partnerships and government relations Mark Simpson added

Patients involved in the Phase One pilot overwhelmingly reported a positive experience. Beyond the technical success of the program, this important comfort and compliance metric shows we can adopt such transformative technologies without detriment to patient satisfaction, sustaining our ongoing commitment to outstanding patient care.

4DMedical share price snapshot

Over the past12 months, the 4DMedical share price has increased around 14%. It's underperformed the All Ords Index by approximately 12 percentage points in that time.

4D Medical has a market capitalisation of around $342 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »